GSK3&#x03B2; activation is a key driver of resistance to Raf inhibition in BRAF mutant melanoma cells

Diana Crisan; Susanne Schatz; Heidi Hainzl; Fang Zhao; Annette Paschen; Maria Crisan; Adrian Baican; Karin Scharffetter-Kochanek; Abhijit Basu

doi:10.18632/oncotarget.28711

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Perspectives:

GSK3β activation is a key driver of resistance to Raf inhibition in BRAF mutant melanoma cells

Diana Crisan, Susanne Schatz, Heidi Hainzl, Fang Zhao, Annette Paschen, Maria Crisan, Adrian Baican, Karin Scharffetter-Kochanek and Abhijit Basu _

PDF | Full Text | Supplementary Files | How to cite

Oncotarget. 2025; 16:257-259. https://doi.org/10.18632/oncotarget.28711

Metrics: PDF 4 views | Full Text 26 views | ?

Abstract

Diana Crisan1, Susanne Schatz2, Heidi Hainzl2, Fang Zhao3, Annette Paschen3, Maria Crisan4, Adrian Baican4, Karin Scharffetter-Kochanek1^,2 and Abhijit Basu2

1 Clinic of Dermatology and Allergic Diseases, University Hospital Ulm, Ulm, Germany

2 Experimental Laboratories of the Department of Dermatology and Allergic Diseases, Ulm, Germany

3 Department of Dermatology, University Hospital Essen, University Duisburg-Essen, Essen and German Cancer Consortium (DKTK), partner site Essen/Düsseldorf, Essen, Germany

4 Department of Dermatology, “Iuliu Hatieganu” University of Medicine and Pharmacy Cluj-Napoca, Romania

Correspondence to:

Abhijit Basu,

email:

[email protected]

Keywords: BRAF melanoma resistance mechanisms; GSK3 β; BRAF mutation

Received: October 01, 2024 Accepted: February 27, 2025 Published: April 04, 2025

Copyright: © 2025 Crisan et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28711

Publication Alerts

Oncoscience

Post-Publication Promotion

Research Perspectives:

GSK3β activation is a key driver of resistance to Raf inhibition in BRAF mutant melanoma cells

Abstract